Inhibitory effect of buddlejasaponin IV on hepatocarcinoma 22 (H_(22)) in mice

To observe the inhibitory effect of buddlejasaponinⅣ on tumor growth on murine transplanted hepatocarcinoma 22(H22)in vivo,tumor inhibitory activities were tested in experimental tumor H22 mice.The tumor bearing mice were randomly divided into control group,CTX group(CTX,20.0mg/kg)and buddlejasaponinⅣ treatment groups(1.00,0.50,0.25mg/kg).The body weight and survival of mice in all groups were recorded.After exposing to medications for 10 days,all the mice were killed on second day,the tumors were taken out and weighted with tumor inhibition rate,and the indexes of spleen and thymus were checked,and the SOD activity,MDA,GGT and AKP levels in serum in each group were detected.The results showed that the high and middle dosage buddlejasaponinⅣ treated groups could inhibit H22 growth compared with the control group(P0.01),the inhibitory rate was56.96%,50.63%respectively.In the high dosage buddlejasaponinⅣ treated groups,the activity of serum SOD increased(P0.05),and in all the buddlejasaponinⅣ treated groups,serum MDA contents decreased(P0.01).Compared with the control group,in all the buddlejasaponinⅣ treated groups,serum GGT,AKP content compared were highly significant differences(P0.01),while the CTX group showed no significant difference.BuddlejasaponinⅣ can inhibit hepatocarcinoma growth.The mechanism may regulate the body antioxidant capacity,and needs further study.